Published online before print April 1, 2002, doi: 10.1161/01.CIR.0000014447.06099.FB
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2002;105:1776.)
© 2002 American Heart Association, Inc.
Clinical Investigation and Reports |
Plasma Homocysteine Concentration, Statin Therapy, and the Risk of First Acute Coronary Events
From the Center for Cardiovascular Disease Prevention and the Leducq Center for Cardiovascular Research, Division of Preventive Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Mass (P.M.R., A.P.D.); Abbott Laboratories, Abbott Park, Ill (J.S.); Merck Research Laboratory, Rahway, NJ (T.J.C.); the University of North Texas Health Science Center, Fort Worth (M.C., S.E.W.); Wilford Hall Medical Center, Lackland Air Force Base, San Antonio, Tex (J.R.D.); and the Weill Medical College of Cornell University, NY (A.M.G.).
Correspondence to Dr Paul M. Ridker, Center for Cardiovascular Disease Prevention, Brigham and Women’s Hospital, 900 Commonwealth Ave East, Boston, MA 02215. E-mail pridker{at}partners.org
Background— Elevated homocysteine levels are associated with increased coronary risk, and it has been suggested that homocysteine screening may provide a method to identify high-risk patients for aggressive primary prevention.
Methods and Results— Homocysteine was measured at baseline and after 1 year among 5569 participants in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS), a randomized trial of lovastatin in the primary prevention of acute coronary events. The effects of homocysteine, LDL cholesterol, and lovastatin on risk were assessed over 5.2 years of trial follow-up. Median baseline homocysteine levels were significantly higher among study participants who subsequently had acute coronary events compared with those who did not (12.1 versus 10.9 µmol/L, P<0.001). The relative risks of future events from lowest (referent) to highest quartile of homocysteine were 1.0, 1.6, 1.6, and 2.2 (P<0.001). These effects were similar among those allocated to lovastatin and those allocated to placebo and were modestly attenuated after adjustment for other traditional risk factors. As predicted, the subgroup of participants with elevated LDL cholesterol and elevated homocysteine levels were at high risk and benefited greatly from statin therapy (relative risk, 0.46; 95% CI, 0.29 to 0.75; number needed to treat=26). However, in contrast to findings in this trial for C-reactive protein, homocysteine evaluation did not help to define low LDL subgroups with different responses to lovastatin therapy.
Conclusions— Although homocysteine predicted future coronary events in AFCAPS/TexCAPS, we found little evidence that homocysteine evaluation provided an improved method to target statin therapy among those with low-to-normal LDL cholesterol levels.
Key Words: prevention • myocardial infarction • lipids • lipoproteins
This article has been cited by other articles:
 |
|
 |
|
  L. G. Mikael and R. Rozen Homocysteine modulates the effect of simvastatin on expression of ApoA-I and NF-{kappa}B/iNOS Cardiovasc Res, July 1, 2008; (2008) cvn157v2. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Siva, M. De Lange, D. Clayton, S. Monteith, T. Spector, and M.J. Brown The heritability of plasma homocysteine, and the influence of genetic variation in the homocysteine methylation pathway QJM, August 1, 2007; 100(8): 495 - 499. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Koebnick, A. L. Garcia, P. C. Dagnelie, C. Strassner, J. Lindemans, N. Katz, C. Leitzmann, and I. Hoffmann Long-Term Consumption of a Raw Food Diet Is Associated with Favorable Serum LDL Cholesterol and Triglycerides but Also with Elevated Plasma Homocysteine and Low Serum HDL Cholesterol in Humans,2 J. Nutr., October 1, 2005; 135(10): 2372 - 2378. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Cesari, M. Zanchetta, A. Burlina, L. Pedon, G. Maiolino, D. Sticchi, A. C. Pessina, and G. P. Rossi Hyperhomocysteinemia Is Inversely Related With Left Ventricular Ejection Fraction and Predicts Cardiovascular Mortality in High-Risk Coronary Artery Disease Hypertensives Arterioscler. Thromb. Vasc. Biol., January 1, 2005; 25(1): 115 - 121. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. H Abdelhadi, M. K Chung, and D. R Van Wagoner New hope for the prevention of recurrent atrial fibrillation Eur. Heart J., July 1, 2004; 25(13): 1089 - 1090. [Full Text] [PDF]
|
|
|
|
 |
|
 P. M Ridker, N. J. Brown, D. E. Vaughan, D. G. Harrison, and J. L. Mehta Established and Emerging Plasma Biomarkers in the Prediction of First Atherothrombotic Events Circulation, June 29, 2004; 109(25_suppl_1): IV-6 - IV-19. [Full Text] [PDF]
|
|
|
|
 |
|
 E. M. Balk, J. Lau, L. C. Goudas, H. S. Jordan, B. Kupelnick, L. U. Kim, and R. H. Karas Effects of Statins on Nonlipid Serum Markers Associated with Cardiovascular Disease: A Systematic Review Ann Intern Med, October 21, 2003; 139(8): 670 - 682. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. De Bree, W. M. Verschuren, D. Kromhout, L. I Mennen, H. J Blom, E. S Ford, S J. Smith, D. F Stroup, K. K Steinberg, P. W Mueller, et al. Homocysteine and coronary heart disease: the importance of a distinction between low and high risk subjects Int. J. Epidemiol., December 1, 2002; 31(6): 1268 - 1272. [Full Text] [PDF]
|
|
|
|
 |
|
 Homocysteine Screening Identifies Only Some Candidates for Primary Prevention with Statins Journal Watch Cardiology, July 12, 2002; 2002(712): 5 - 5. [Full Text]
|
|
|
|
 |
|
 Plasma Homocysteine in Primary Prevention of Coronary Events? Journal Watch (General), May 28, 2002; 2002(528): 1 - 1. [Full Text]
|
|